Kamada to Announce Second Quarter Ended

Kamada to Announce Second Quarter Ended

June 30, 2020 Financial Results and Host

Conference Call on August 12, 2020

Rehovot, Israel, August 5, 2020 --

Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial

results for the second quarter ended June 30, 2020, prior to the open of the U.S. financial markets on Wednesday, August 12, 2020.

Kamada management will host an investment

community conference call on Wednesday, August 12, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders

and other interested parties may participate in the conference call by dialing 855-327-6837 (from within the U.S.), 1-809-458-327

(from Israel), or 631-891-4304 (International) and entering the conference identification number: 10010379. The call will also

be webcast live on the Internet on the Company's website at www.kamada.com.

call will also be archived for 90 days on the Company's website at www.kamada.com.

Kamada Ltd. ("the Company")

is a commercial stage plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product

portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction

and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well

as other plasma-derived immune globulins. The Company's flagship product is GLASSIA , the first liquid, ready-to-use,

intravenous plasma-derived AAT product approved by the U.S. FDA. The Company markets GLASSIA in the U.S. through a strategic partnership

with Takeda Pharmaceuticals Company Limited and in other countries through local distributors. The Company's second leading

product is KamRab , a rabies immune globulin (Human) for post-exposure prophylaxis against rabies infection. KamRab is FDA

approved and is being marketed in the U.S. under the brand name KEDRAB through a strategic partnership with Kedrion S.p.A.

In addition to Glassia and KEDRAB, the Company has a product line of four other plasma-derived pharmaceutical products administered

by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India

and other countries in Latin America and Asia. The Company has late-stage products in development, including an inhaled formulation

of AAT for the treatment of AAT deficiency. In addition, the Company's intravenous AAT is in development for other indications,

such as GvHD and prevention of lung transplant rejection. The Company leverages its expertise and presence in the plasma-derived

protein therapeutics market by distributing more than 20 complementary products in Israel that are manufactured by third parties.

FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning

approximately 21% of the outstanding ordinary shares.

Chief Financial Officer

LifeSci Advisors, LLC